IRCT20191030045275N1Not yet recruitingPhase 2
Efficacy and Safety of moxidectin versus ivermectin for treatment of human scabies: A randomized clinical trial
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- no limit to 60 years (—)
- Sex
- All
Inclusion Criteria
- •(A) Clinical: 1. Intense pruritus especially at night. 2. Typical distribution of the excoriated papulovesicular lesions; around umbilicus, flexures, genitalia, interdigital spaces. 3. Affection of other family members.
- •(B) Parasitological: By detection of Sarcoptes Scabeii mites (adult, larvae and eggs) in cutaneous scrapings.
Exclusion Criteria
- •Patients with recent topical or systemic treatments of scabies.
- •Patients with clinical bacterial infection or any other associated skin disease.
- •Patients with any evident systemic diseases causing pruritus.
- •Pregnant and lactating women.
Investigators
Similar Trials
Completed
Not Applicable
Efficacy of a moxidectin versus ivermectin in subjects infected by Strongyloides stercoralisStrongyloides stercoralis infectionInfections and InfestationsISRCTN11983645Swiss Tropical and Public Health Institute (Swiss TPH)120
Completed
Phase 3
Moxidectin for LF, Cote d'Ivoire (DOLF)Lymphatic FilariasisNCT04410406Washington University School of Medicine164
Completed
Phase 3
Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus InfectionOnchocerciasisNCT00790998Medicines Development for Global Health1,497
Completed
Phase 2
Evaluating the effect of Ivermectin on covid 19 patientsCOVID 19.Corona virus infection, unspecifiedU07.1IRCT20200404046937N4Ahvaz University of Medical Sciences60
Completed
Phase 1
Efficacy and safety of Ivermectin for the treatment of Plasmodium falciparum infections in asymptomatic Gabonese adultsMalariaPACTR201908520097051Centre de Recherches Medicales de Lambarene49